UT Dallas

The Last Word: OptiMIND Founder on Winning a $40,000 Award for Research Innovation at UTD’s Big Idea Competition

Associate Professor Chandramallika Basak entered UTD's recent Big Idea Competition in the alumni research commercialization category with OptiMIND, a series of brain training games designed to enhance brain and cognition across the lifespan. The games are designed to ensure that people stay sharp and focused at any age. After winning $40,000 in the competition, she recently tweeted that she's ready to start her startup.
MORE
The Last Word: Omni Hotel’s Ruth Andrews on UTD Students’ Animations for Dallas Arts Month
by | Apr 19, 2023
To celebrate Dallas Arts Month, the Omni Dallas Hotel is displaying 16 animations by UTD Projection Mapping Lab students on select nights through the end of the April, from 8:30 to 11:30 p.m.
MORE
The Last Word: Dr. Kangkook Jee on How UTD Students Are Making Their Mark in National Competitions
From an NSA Codebreaker Challenge to an offshore wind farm competition to one of the world's toughest-to-crack mathematics competitions, UT Dallas teams keep showing up and making the mark.
MORE
The Last Word: UTD’s Dale MacDonald on How AI Chatbots Could Impact Your Job
by | Mar 29, 2023
MacDonald was part of a panel discussion at UT Dallas, in partnership with The Dallas Morning News, aimed at clearing up misconceptions about ChatGPT, the AI chatbot that’s gone viral. The panel featured four UTD scientists—Xinya Du, Gopal Gupta, Dale MacDonald, and Jessica Ouyang—and was moderated by Adithi Ramakrishnan, science reporter at the DMN.
MORE

CPRIT Awards Over $20M to UT Southwestern and UT Dallas to Fight Cancer

The Cancer Prevention and Research Institute of Texas approved over $90 million in new cancer research and prevention grants at its quarterly meeting near the Texas Capitol on Wednesday—and $20.6 million of that money is coming to North Texas to advance everything from breast cancer and lung cancer screening to "deep learning models" to facilitate T-cell receptor therapies.
MORE
Ziflow’s Dallas Team is Slated for Growth After $20M Series A Raise
Headquartered in London with go-to-market operations in Dallas, Ziflow aims to grow its North Texas team from 28 to over 40 in the next 12-18 months. Its enterprise creative workflow platform helps companies like Showtime and McCann Worldgroup centralize feedback "on any creative asset using any device."
MORE
Dallas’ MedCognetics Gets $750K NIH Grant to Research Unbiased AI for Breast Cancer Detection
by | Jan 26, 2023
Last month, we told you about MedCognetics getting FDA clearance for its unbiased AI-enabled software for breast cancer screening. Today, the Dallas-based company announced it has been awarded $750,000 from an NIH program to research unbiased AI for breast cancer detection. The NIH's AIM-AHEAD program—short for Artificial Intelligence/Machine Learning Consortium to Advance Health Equity and Researcher Diversity—awarded the grant. "This NIH grant will play an important role in future product development as well as helping us further expand our global market penetration," said MedCognetics CEO Debasish Nag.
MORE

Ericsson’s Kevin Zvokel on 10 Hot Consumer Trends, His Company’s ‘Factory of the Future’ in Lewisville, and More

Ericsson's new report, "10 Hot Consumer Trends: Life in a Climate-Impacted Future," is packed with insights on what consumers—including those in DFW—believe is looming on the way to the 2030s. We spoke with Kevin Zvokel, head of networks for Plano-based Ericsson North America, about both the report and his company's innovative impact across North Texas.
MORE
Dallas’ MedCognetics Gets FDA Clearance for Its AI-Enabled Breast Cancer Screening Software
by | Dec 20, 2022
The early-stage startup's QmTRIAGE software platform uses AI and machine learning to detect early breast cancers with a "high rate" of accuracy, MedCognetics says. The company has worked with UT Southwestern and UT Dallas to ensure its AI improves outcomes for "all ethnicities," at a time when racial disparities in AI have become a growing concern.
MORE
UTD’s Dr. Amy Pinkham Picked to Head Global Initiative to Standardize Schizophrenia Assessment
by | Dec 9, 2022
Dr. Amy Pinkham of UTD’s School of Behavioral and Brain Sciences received an award for outstanding research on social cognition. The award puts her group at the forefront of research in the field, the professor said.

The work could be applicable for many disorders, including autism and mood and anxiety disorders.
MORE
The Last Word: UTD’s Dr. Amy Pinkham on Heading a Global Initiative to Standardize Schizophrenia Assessment
Dr. Amy Pinkham of UTD’s School of Behavioral and Brain Sciences received an award for outstanding research on social cognition. The award puts her group at the forefront of research in the field, the professor said. The work could be applicable for many disorders, including autism and mood and anxiety disorders.
MORE
math

UT Dallas and Novartis Are Using Math to Speed Drug Discoveries

“The advantage of our algorithm is that it could screen about 100,000 compounds in a couple of days, which is much faster than other methods,” UT Dallas' Dr. Baris Coskunuzer says.
MORE
How Axxess’ John Olajide Built a Bootstrapped Unicorn in Dallas
Axxess founder John Olajide built his Dallas-based healthcare tech company from a fledgling startup in 2007 to a global company with 1,000 employees serving 3 million-plus patients. But the journey getting there wasn’t a straightforward path. 

He tells his own story to inspire others and strengthen the ecosystem. And he's confident that "we'll be celebrating several more unicorns going forward."
MORE
With New Center, UT Dallas Researchers Are Looking into the Molecular Causes of Pain
With a five-year, $11.3 million grant from the National Institute of Neurological Disorders and Stroke, researchers at UT Dallas' new Human Nociceptor and Spinal Cord Molecular Signature Center are digging into the causes of chronic pain and new ways to treat it. The center's leader, Dr. Ted Price, says the data generated "will fundamentally change the way that we think about pain and how we develop therapeutics."
MORE